Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophagea...(all signs of dysplasia. These data comp...),Health

A European multi-center randomized trial included 47 patients with Barrett's containing dysplasia and early cancer that were randomized to receive either endoscopic resection or radiofrequency ablation with the HALO ablation system. While both interventions had very high complete eradication rates (95-100%), endoscopic resection was associated with a significantly higher risk of complications. Based on these results, investigators concluded that the optimal approach is to focally resect visible lesions followed by radiofrequency ablation for complete eradication of the remaining Barrett's tissue.

In the largest European series reported to date, "Radiofrequency Ablation for Eradication of Barrett's Esophagus Containing High-Grade Dysplasia or Early Cancer: A Prospective Series of 73 Patients," researchers combined a baseline focal endoscopic resection for disease staging, and then applied serial RFA with the HALO ablation system. A complete response was achieved in 95% of patients without occurrence of serious adverse events.

"Barrett's esophagus places a patient at a significantly higher risk for developing esophageal adenocarcinoma," commented David S. Utley, M.D., chief medical officer for BARRX Medical. "Researchers at this national meeting are reporting the results of a number of well-designed clinical trials using endoscopic radiofrequency ablation to completely eradicate the Barrett's tissue. Each unique study design offers new data that continues to establish an evidence-based role for radiofrequency ablation in managing this disease state."

About BARRX Medical, Inc.

BARRX Medical, Inc. develops treatment solutions for Barrett's esophagus, a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or
'/>"/>